UNSPSC 51182049: Clostebol propionate

This classification denotes an anabolic steroid C22H31ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JJ3052NOU, chemically known as androst-4-en-3-one, 4-chloro-17-(1-oxopropoxy)-, (17.beta.)-, but more generally known as clostebol propionate, which bears US NIH Compound Identifier 71586790. Most nations, for tariff and trade purposes, schedule clostebol propionate under HS 29372900 and SITC 54153. As of Q4 2014, CLOSTEBOL PROPIONATE remains US FDA's Preferred Term for this commodity.

SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C(C(=O)CC[C@]34C)CL)C.

UNSPSC 51182049 Clostebol propionate is a Commodity code covering a synthetic anabolic steroid used in medical and veterinary applications. State and local governments procure clostebol propionate primarily through health departments, correctional facilities, and public hospitals for therapeutic use in treating muscle-wasting conditions, delayed puberty, and certain types of anemia. The code also serves veterinary agencies and animal-control facilities managing livestock and companion-animal health. Issuing bodies typically include state health departments, county public-health systems, city hospitals, and regional correctional authorities. Procurement under this code remains modest in volume relative to other pharmaceutical commodities, reflecting the narrow clinical indications and controlled-substance regulatory requirements that govern distribution and use.

The source provides no recent state or local contract opportunities under this code. Activity, when present, concentrates among state correctional systems and large urban public-hospital networks, though the sparse recent record limits geographic characterization. Procurement is typically conducted through pharmaceutical group-purchasing organizations and state cooperative contracts rather than individual competitive solicitations, which reduces visibility in standard RFP and RFQ channels. Organizations evaluating pursuit under this code should monitor state health-department and corrections-agency cooperative vehicle updates and direct-award schedules with qualified pharmaceutical distributors rather than anticipate standalone competitive notices.